Reslizumab (Sch 55700) is a humanized monoclonal antibody designed to specifically target and neutralize interleukin-5 (IL-5), a key cytokine involved in the pathogenesis of eosinophilic asthma. This antibody exhibits a high binding affinity for human IL-5, demonstrating dissociation constants (K_D) of 109 pM and 4.3 pM in Biacore surface plasmon resonance and Kinetic Exclusion Assay analyses, respectively. By inhibiting the activity of IL-5, Reslizumab effectively reduces the growth and survival of eosinophils, thereby mitigating the inflammatory processes associated with eosinophilic asthma. This makes Reslizumab a critical tool in the therapeutic management of this condition.
Reslizumab (Sch 55700) is a humanized monoclonal antibody designed to specifically target and neutralize interleukin-5 (IL-5), a key cytokine involved in the pathogenesis of eosinophilic asthma. This antibody exhibits a high binding affinity for human IL-5, demonstrating dissociation constants (K_D) of 109 pM and 4.3 pM in Biacore surface plasmon resonance and Kinetic Exclusion Assay analyses, respectively. By inhibiting the activity of IL-5, Reslizumab effectively reduces the growth and survival of eosinophils, thereby mitigating the inflammatory processes associated with eosinophilic asthma. This makes Reslizumab a critical tool in the therapeutic management of this condition.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
